Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry

/PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central...

Related Keywords

New York ,United States ,Massachusetts ,Americans ,American ,Herriot Tabuteau ,Mark Jacobson ,Prnewswire Axsome Therapeutics Inc ,Axsome Therapeutics Inc ,Drug Administration ,Harvard Medical School ,Department Of Psychiatry ,Nasdaq ,Dean For Clinical Translational Research ,Clinical Trials Network Institute ,Major Depressive Disorder ,Clinical Trial ,Clinical Psychiatry ,Maurizio Fava ,Massachusetts General Hospital ,Executive Director ,Clinical Trials Network ,Associate Dean ,Translational Research ,Slater Family Professor ,American Journal ,Chief Executive Officer ,Depression Rating Scale ,Axsome Therapeutics ,